Why do hospital prescribers continue antibiotics when it is safe to stop? Results of a choice experiment survey
ROOPE L. et al, (2020), BMC Medicine
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling
Marshall DA. et al, (2020), Value in Health
How did a Quality Premium financial incentive influence antibiotic prescribing in primary care? Views of Clinical Commissioning Group and general practice professionals
BOREK A. et al, (2020), Journal of Antimicrobial Chemotherapy
Implications of secondary findings for clinical contexts
MORRISON M. et al, (2020), Secondary Findings in Genomic Research, 155 - 201
Estimating the effect of healthcare-associated infections on excess length of hospital stay using inverse-probability weighted survival curves
Pouwels KB. et al, (2020), Clinical Infectious Diseases
Essential items for a Health Economics Analysis Plan (HEAP): expert Delphi consensus survey
Thorn J. et al, (2019), TRIALS, 20
A review of health economic studies comparing traditional and massively parallel sequencing diagnostic pathways for suspected genetic disorders
Fahr P. et al, (2019), PharmacoEconomics
In Hospital Clinical Efficacy, Safety and Oncologic Outcomes from VIOLET: A UK Multi-Centre RCT of VATS Versus Open Lobectomy for Lung Cancer
Lim E. et al, (2019), JOURNAL OF THORACIC ONCOLOGY, 14, S6 - S6
A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study
(2019), Health Services and Delivery Research
Implementation of a genomic medicine multi-disciplinary team approach for rare disease in the clinical setting: a prospective exome sequencing case series.
Taylor J. et al, (2019), Genome Med, 11
Do health professionals value genomic testing? A discrete choice experiment in inherited cardiovascular disease
BUCHANAN JAMES. et al, (2019), European Journal of Human Genetics
Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention?
Morton RL. et al, (2019), Cancer Epidemiol, 61, 8 - 13
The challenge of antimicrobial resistance: What economics can contribute
Roope LSJ. et al, (2019), Science, 364, eaau4679 - eaau4679
A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine
Fahr P. et al, (2019), Applied Health Economics and Health Policy
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2019), BMC health services research, 19, 198 - 198